VitaDAO 2024 Highlights

January 29, 2025

•

‍

‍

High-Level KPI

Token Holders: total of 8,500+ across all blockchains (250% YoY growth)

‍

Scientific Updates

VitaDAO's projects showed promising developments towards medicines that could slow or reverse aging by reprogramming aged cells, removing toxic aging cells, and treating other age-related conditions:

AB4AD - Successfully identified and validated 31 proteins that showed significant immune response in AD patients or controls. Some of them are preferentially targeted in Alzheimer's patients, while others may show a stronger reaction in old cognitively-intact individuals.
Etheros Pharma in-vivo testing confirmed a large therapeutic window for their lead molecule, and has succeeded in creating a number of new compounds for potential new applications.
The Exercise & Rapamycin clinical trial co-funded by VitaDAO under the leadership of Dr Stanfield has completed the data collection phase. Data analysis will start shortly and results should be published in a few months. Protocol available here.
Mantis Photonics tested their hyperspectral ocular imaging technology in a small clinical trial with 57 people, obtaining 93% accuracy in diagnosing Alzheimer’s. These results will be published soon.
Oisin Bio published a paper on the safe and effective in vivo delivery of DNA and RNA using their proteolipid vehicles in collaboration with Entos.
Remedium Bio published preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™ in a paper on the Gene journal.
Vita-FAST went through two iterations of lead series reaching nanomolar potency at inducing autophagy.
VitaRNA successfully identified from a series of candidate oligos a promising lead oligo and validated it in combination with an AAV. The project is currently raising $1M in a follow-on crowdsale for drug formulation and testing in animal models.

‍

Business updates

Cyclarity Therapeutics announced the closing of the first tranche of its Series A funding round, led by Ki Tua Fund LP and Starbloom Primrose LP. They will use the funds to commence clinical trials or the development of UDP-003, a novel therapeutic designed to reduce atherosclerotic plaque accumulation.
HDAX Therapeutics raised a $3.2M seed round for developing HDAC6 inhibitors with blood-brain barrier penetration capabilities.
The Longevity Hackers Movie co-funded by VitaDAO has completed production and is now available in VOD on Apple TV, Prime Video, Google Play, Vudu, and soon on Fandango. More information here.
Oisín Biotechnologies announces the first close of $15 million series A financing round to advance therapies for age-related diseases, with AbbVie ventures leading the round.
Repair Biotechnologies advanced their Cholesterol Degrading Platform for atherosclerosis treatment, completing CMC work and pre-IND package. They just announced a positive pre-IND Meeting with FDA for their lead REP-0003 to treat homozygous familial hypercholesterolemia.
Rubedo Life Sciences secured a $40M Series A funding and advances to human trials, developing selective "smart drugs" targeting senescent cells. They also hired a seasoned biotech CEO and expanded in Europe. Finally, the named their clinical candidate at JPM, becoming the second clinical-stage company in VitaDAO’s portfolio.
Turn Bio signed a $300M+ licensing deal with HanAll Biopharma for eye/ear therapies; reported significant skin cell rejuvenation results at ESDR Conference.

Core Initiatives

‍

VitaLabs

VitaDAO launched VitaLabs in Q4-24, an initiative designed to create an in-house network of interdisciplinary scientists dedicated to pioneering cutting-edge longevity science. Our mission is to radically extend human healthspan and lifespan by developing cutting-edge research while empowering democratic ownership of Intellectual Property through IPTs.

The Fellowship Program, designed to attract top tier talent for the inaugural VitaLabs season received over 70 applications and 12 innovative project submissions. The community has selected four exciting projects to receive support from VitaDAO through a quadratic governance proposal.

‍

Products

VD-001: The first VitaDAO longevity product launched successfully with:

Thai FDA approval secured
High-doses of spermidine
A presentation to industry leaders including CZ Binance and Vitalik Buterin during DeSci Day at the Binance Labs BUIDLer House in Bangkok

What’s Next (Q1-25)

Compounds from The Longevity Prize will soon be launched on pump.science
Introduction of expanded product line focusing on innovative longevity formulations
Supplements pre-order system and official marketplace goes live with exclusive discounts to community members

AI Agents

Our experiments with various agent frameworks have been nothing short of mind-blowing, and we see multiple ways to leverage their capabilities to advance our mission. By integrating AI Agents deeply into our research and operational workflows, we aim to unlock new efficiencies, accelerate discovery, and create novel avenues for collaboration.

Development of the first DeSci AI agent: Together with BIO, we are developing an AI Agent designed to impersonate Aubrey de Grey providing community members with 1. actionable longevity insights and advice aligned with Aubrey’s well-known reasoning; 2. live updates about the RMR2 study to keep the community informed about the development of the study and 3. growth and excitement through meme creation and shareable content.

Partnership with YNE: We have also been amazed by the latest breakthroughs from the Yes or No Error (YNE) team and are thrilled to announce a new partnership. Initially, the plan is to have YNE publicly auditing research findings from several of our core projects, providing an added layer of transparency and rigor. In the future, we aim to expand this collaboration to include other initiatives such as VitaLabs, ensuring robust real-time verification and accountability across our entire research ecosystem.

Team expansion

VitaDAO is hiring aggressively to fuel its next stage of growth. Key roles include:

*already negotiating terms with selected candidates

If you know of any outstanding candidates or have recommendations within your network, we would greatly appreciate your support and referrals!

We want to express our deepest gratitude for your unwavering support. It has been a remarkable journey filled with both challenges and breakthroughs, and we truly appreciate you standing with us every step of the way. We’re more excited than ever about what lies ahead and look forward to continuing this journey together.

Thank you for being a part of our story!

‍

VitaDAO team